Source link : https://newshealth.biz/health-news/obexelimab-lowers-flare-risk-in-phase-3-igg4-rd-trial/
Weekly subcutaneous injections of the novel B-cell inhibitor obexelimab significantly reduces disease flares and lowers toxic steroid exposure in patients with active IgG4-related disease. Medscape Medical News Source link : https://www.medscape.com/viewarticle/b-cell-inhibitor-obexelimab-safe-effective-igg4-related-2026a1000iti?src=rss Author : Publish date : 2026-06-05 07:27:00 Copyright for syndicated content belongs to the linked Source.
The post Obexelimab Lowers Flare Risk in Phase 3 IgG4-RD Trial first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-05 07:27:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8